Researchers at the Medical University of South Carolina (MUSC) have identified a fundamental defect in the protein repair systems of patients with idiopathic dilated cardiomyopathy (IDCM). According to a 2026 study published in the Journal of Molecular and Cellular Cardiology, this breakdown in cellular maintenance leads to the accumulation of misfolded protein plaques, mirroring processes seen in Alzheimer’s disease and potentially linking heart failure to neurological health.
Why do protein plaques form in the heart?
The formation of these plaques stems from a failure in the heart’s machinery to manage damaged proteins. As detailed by senior author Federica del Monte, M.D., Ph.D., and her team, the issue lies in post-translational modifications (PTMs)—the chemical alterations that regulate repair proteins. Their research, which earned a journal cover and editor’s choice distinction, discovered that these PTMs shift toward promoting cell death rather than repair. This dysfunction leaves the heart unable to handle the stress of misfolded proteins, effectively turning the condition into a protein misfolding disease similar to Alzheimer’s.
The del Monte Lab’s research suggests that IDCM characteristics may manifest in the heart before Alzheimer’s symptoms appear in the brain, leading researchers to suggest the heart could serve as a “window to the brain.”
How can the heart serve as a window to the brain?
The multidisciplinary approach taken by the MUSC team has bridged the gap between cardiology and neurology. Because IDCM and Alzheimer’s share molecular characteristics, the lab is advocating for cross-clinic screening. Camilla Bacchin, M.D., a co-first author of the paper, notes that early detection through heart ultrasounds—specifically looking for an enlarged or weakened left ventricle—could allow for earlier intervention. The goal is to prevent the disease from worsening by treating the underlying protein repair failure before it reaches an advanced stage.
What is the future of IDCM treatment?
Moving from the laboratory bench to the bedside requires a comprehensive understanding of the entire protein repair system. Federica del Monte emphasizes that because these repair mechanisms are already being explored in cancer research, there is potential for repurposing similar diagnostic or therapeutic strategies for IDCM. Future studies aim to validate these molecular changes as early biomarkers of disease. This effort is supported by a decade-long international collaboration involving researchers like Marco Luciani, M.D., Ph.D., Luca Trocone, Ph.D., and Cristina Balla, M.D., Ph.D., who continue to advance this work across institutions in the U.S., Switzerland, and Italy.
Frequently Asked Questions
What is IDCM?
Idiopathic dilated cardiomyopathy (IDCM) is a heart muscle condition that often remains undetected until it progresses to advanced heart failure.
What is the link between heart failure and Alzheimer’s?
Research from the del Monte Lab shows that both conditions involve the accumulation of misfolded protein plaques and defects in the body’s protein repair machinery.
Can doctors screen for IDCM?
Yes, medical professionals can screen for IDCM by using heart ultrasounds to identify physical signs such as an enlarged or weakened left ventricle.
Are you interested in the intersection of heart health and neurology? Subscribe to our research newsletter for the latest updates on multidisciplinary breakthroughs, or explore our archives to learn more about how molecular discoveries are changing patient care.
